{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:57:18Z","timestamp":1783699038603,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Impressive advances in immunotherapy especially immune checkpoint inhibitors have made great progress in treating multiple cancers but can also cause serious even incurable immune-related adverse events, mostly found in colitis, dermatitis, hepatitis, and thyroiditis patients. Rare autoimmune hematologic toxicities have been reported in the literature, but are poorly described. Aplastic anaemia induced by immune checkpoint inhibitors is a life-threatening autoimmune disease; however, only a few cases have been reported in the literature.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> To characterize and evaluate Aplastic anaemia associated with different ICI regimens in public database and review the literature.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We described a case series of patients experiencing Aplastic anaemia while on immune checkpoint inhibitors. We also mined the Food and Drug Administration\u2019s Adverse Event Reporting System and used reporting odds ratio, the proportional reporting ratio, the Bayesian confidence propagation neural network and the multi-item gamma Poisson shrinker algorithms to achieve the data of the suspected adverse events of Aplastic anaemia-induced by immune checkpoint inhibitors between January 2011 and June 2022.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Thirteen patients with Aplastic anaemia events while on immune checkpoint inhibitors were included in our case series, and seven of them had a fatal outcome. In FAERS, a total of 38 individual case safety reports (immune checkpoint inhibitors) with different ICI regimens were retrieved, of which 25 (65.79%) were reported as monotherapy and 13 (34.2%) had a fatal outcome. The reporting odds ratio was significant for nivolumab (reporting odds ratio 3.05, 95%CI 1.73\u20135.38), pembrolizumab (reporting odds ratio 2.33, 95%CI 1.16\u20134.67), avelumab (reporting odds ratio 12.63, 95%CI 3.15\u201350.62) and ipilimumab\/nivolumab (ROR 2.57, 95%CI 1.15\u20135.72).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> There is a significant reporting signal of Aplastic anaemia with several ICI agents. Clinicians should raise awareness and monitor this potentially fatal adverse event.<\/jats:p>","DOI":"10.3389\/fphar.2023.1057134","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T05:04:11Z","timestamp":1674709451000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Immune checkpoint inhibitor-induced aplastic anaemia: Case series and large-scale pharmacovigilance analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Qian","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Ning","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Min","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1182\/blood-2016-08-693481","article-title":"How I treat acquired aplastic anemia","volume":"129","author":"Bacigalupo","year":"2017","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"6576","DOI":"10.1002\/cam4.3198","article-title":"Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data","volume":"9","author":"Chen","year":"2020","journal-title":"Cancer Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e37211","DOI":"10.3897\/biodiscovery.22.e37211","article-title":"Aplastic anemia induced by nivolumab before a treatment of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia","volume":"22","author":"Cheng","year":"2019","journal-title":"BioDiscovery"},{"key":"B5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/1078155217726159","article-title":"Nivolumab-induced aplastic anemia: A case report and literature review","volume":"25","author":"Comito","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"24","author":"Davis","year":"2019","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/s2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: A descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"NP48","DOI":"10.1177\/0300891619856197","article-title":"Unexpected serious aplastic anemia from PD-1 inhibitors: Beyond what we know","volume":"105","author":"Filetti","year":"2019","journal-title":"Tumori"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-021-04690-x","article-title":"Current challenges of hematologic complications due to immune checkpoint blockade: A comprehensive review","volume":"101","author":"Ghanem","year":"2022","journal-title":"Ann. Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"100686","DOI":"10.1016\/j.currproblcancer.2020.100686","article-title":"A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab","volume":"45","author":"Goda","year":"2021","journal-title":"Curr. Probl. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/annonc\/mdx177","article-title":"Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma","volume":"28","author":"Helgadottir","year":"2017","journal-title":"Ann. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.13853","article-title":"Guidelines for the diagnosis and management of adult aplastic anaemia","volume":"172","author":"Killick","year":"2016","journal-title":"Br. J. Haematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40364-021-00314-8","article-title":"Risk factors for immune-related adverse events: What have we learned and what lies ahead?","volume":"9","author":"Liu","year":"2021","journal-title":"Biomark. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40164-018-0098-5","article-title":"Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: A case report","volume":"7","author":"Meyers","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.04.004","article-title":"Immune-related bone marrow failure following anti-PD1 therapy","volume":"80","author":"Michot","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell. Commun. Signal"},{"key":"B19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/25785826.2020.1785654","article-title":"Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy","volume":"44","author":"Nakajima","year":"2021","journal-title":"Immunol. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000500856","article-title":"AIHA and pancytopenia as complications of pembrolizumab therapy for metastatic melanoma: A case report","volume":"12","author":"Ni","year":"2019","journal-title":"Case Rep. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.3389\/fimmu.2020.01354","article-title":"Diagnosis and management of hematological adverse events induced by immune checkpoint inhibitors: A systematic review","volume":"11","author":"Omar","year":"2020","journal-title":"Front. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11864-017-0511-z","article-title":"Diagnosis and treatment of aplastic anemia","volume":"18","author":"Peslak","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000495980","article-title":"Nivolumab induced lethal aplastic anemia in a patient with metastatic melanoma","volume":"12","author":"Rouvinov","year":"2019","journal-title":"Case Rep. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"J Lancet Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: A pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res. Treat."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/hon.2743","article-title":"Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019","volume":"38","author":"Ye","year":"2020","journal-title":"Hematol. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13223-021-00616-4","article-title":"Aplastic anemia secondary to dual cancer immunotherapies a physician nightmare: Case report and literature review","volume":"17","author":"Younan","year":"2021","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/TCRM.S193338","article-title":"Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients","volume":"15","author":"Zhou","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"B30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/1759-7714.13281","article-title":"Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events","volume":"11","author":"Zhuang","year":"2020","journal-title":"Thorac. Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1057134\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T05:04:15Z","timestamp":1674709455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1057134\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":30,"alternative-id":["10.3389\/fphar.2023.1057134"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1057134","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]},"article-number":"1057134"}}